首页 | 本学科首页   官方微博 | 高级检索  
检索        

乳腺癌患者中肿瘤异常糖链蛋白的表达情况及与新辅助化疗疗效的关系
引用本文:包兆康,程家乐,俞士尤.乳腺癌患者中肿瘤异常糖链蛋白的表达情况及与新辅助化疗疗效的关系[J].癌症进展,2020(8):835-837.
作者姓名:包兆康  程家乐  俞士尤
作者单位:南京医科大学附属苏州医院甲乳外科
摘    要:目的探讨乳腺癌患者中肿瘤异常糖链蛋白(TAP)的表达情况及与新辅助化疗疗效的关系。方法选择80例行新辅助化疗的乳腺癌患者和80例乳腺良性肿瘤患者,分别作为观察组和对照组。检测并比较两组患者的血清TAP水平,分析化疗前不同临床特征乳腺癌患者的TAP水平以及不同临床疗效乳腺癌患者化疗前后的TAP水平。结果观察组患者化疗前的TAP水平明显高于对照组,差异有统计学意义(P﹤0.01)。化疗前,临床分期为Ⅲ期、有淋巴结转移乳腺癌患者的TAP水平分别明显高于临床分期为Ⅱ期、无淋巴结转移的患者,差异均有统计学意义(P﹤0.01)。化疗后部分缓解(PR)患者的TAP水平低于化疗前,疾病进展(PD)患者的TAP水平高于化疗前,差异均有统计学意义(P﹤0.05)。化疗后,PR患者的TAP水平低于疾病稳定(SD)和PD患者,SD患者的TAP水平低于PD患者,差异均有统计学意义(P﹤0.05)。结论乳腺癌患者的血清TAP水平较高,TAP水平可能与患者的临床特征有关,且可能在预测化疗疗效方面具有一定的价值。

关 键 词:乳腺癌  肿瘤异常糖链蛋白  新辅助化疗  临床特征

The expression of tumor abnormal protein in breast cancer patients and its relationship with efficacy of neoadjuvant chemotherapy
BAO Zhaokang,CHENG Jiale,YU Shiyou.The expression of tumor abnormal protein in breast cancer patients and its relationship with efficacy of neoadjuvant chemotherapy[J].Oncology Progress,2020(8):835-837.
Authors:BAO Zhaokang  CHENG Jiale  YU Shiyou
Institution:(Department of Thyroid and Breast Surgery,Suzhou Municipal Hospital Affiliated to Nanjing Medical University,Suzhou 215000,Jiangsu,China)
Abstract:Objective To investigate the expression of tumor abnormal protein(TAP) in breast cancer patients and its relationship with the efficacy of neoadjuvant chemotherapy.Method A total of 80 patients with breast cancer undergoing neoadjuvant chemotherapy,and 80 patients with benign breast tumors were included in the analysis as study group and control group,respectively.The levels of serum TAP in the two groups were detected,and the TAP level among patients with varying clinical characteristics before chemotherapy were analyzed,besides,pre-and post-chemotherapy TAP levels in breast cancer patients with differing clinical efficacy were investigated.Result The level of TAP in study group before chemotherapy was significantly higher than that in the control group(P<0.01).Before chemotherapy,clinical stage Ⅲ and positive lymph node metastasis were associated with significantly increased TAP compared to clinical stage Ⅱ and negative lymph node metastasis(P<0.01).After chemotherapy,decreased TAP in patients with partial response(PR) was evident,while increased TAP was noted among those who with progressive disease(PD)(P<0.05).The greatest reduction of TAP was observed in patients with PR after chemotherapy,followed by SD and PD,sequentially,with statistically significant differences found(P<0.05).Conclusion The serum TAP level in breast cancer patients was relatively high,and is likely related to the clinical characteristics of patients,thereby suggesting its value in predicting the efficacy of chemotherapy.
Keywords:breast cancer  tumor abnormal protein  neoadjuvant chemotherapy  clinical characteristic
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号